Soft-tissue response to injectable calcium phosphate cements.

The primary aim of this study was to assess the soft-tissue response to two newly developed injectable calcium phosphate bone cements after implantation in goats. The researchers wanted to determine whether these materials could be safely used in proximity to soft tissues without eliciting harmful reactions. A secondary objective was to evaluate how varying the concentration of the accelerator Na₂HPO₄ in one of the cements affected tissue interactions. The study was designed to provide insights into the biocompatibility of these materials in non-bony environments. The motivation stemmed from the lack of data on how such cements behave when placed near soft tissues rather than bone. The researchers also aimed to identify any correlations between cement formulation and the presence of inflammatory responses. By using a standardized implantation protocol, the study sought to ensure reproducibility of findings. The ultimate goal was to support the development of injectable cements suitable for soft-tissue applications.

The study involved eight mature female Saanen goats, each receiving multiple implantations of the test cements. Two formulations—cement D and cement W—were evaluated, with cement D further tested at two different accelerator concentrations (D1 and D2). The cements were implanted in the goats' backs after being mixed and shaped into standardized cylindrical forms. The implants were left in place for durations of 1, 2, 4, and 8 weeks. At each time point, eight specimens per formulation were retrieved for analysis. Two of these were analyzed using X-ray diffraction (XRD) and Fourier Transform Infrared Spectroscopy (FTIR) to assess material setting. Six specimens were used for histological evaluation to examine tissue reactions. The experimental design allowed for comparisons between cement types and healing periods while controlling for implantation conditions.

XRD and FTIR analyses confirmed that both cements set into microcrystalline carbonate apatite during implantation. Histological examination revealed the formation of a thin soft-tissue capsule around all implants after 8 weeks, with thickness ranging from 5 to 15 cell layers. Inflammatory cell infiltration was nearly absent in most cases, indicating a favorable biocompatibility profile. However, some specimens showed slightly elevated inflammatory responses, which were attributed to cement surface defects and particle dispersion near the implant interface. Minimal resorption of the cement material was observed after 8 weeks of implantation. In a few samples, small calcification areas were detected within the fibrous capsule surrounding the implants. These findings suggest that the cements remained stable and did not trigger significant degradation or immune responses. The results indicate that both cement formulations were well-tolerated by the surrounding soft tissues.

The authors concluded that the tested injectable calcium phosphate cements exhibited biocompatibility when placed in soft-tissue environments. The formation of a thin fibrous capsule and minimal inflammatory response supported their suitability for use near soft tissues. The absence of significant resorption or adverse reactions after 8 weeks of implantation reinforced this conclusion. Variations in accelerator concentration did not appear to significantly impact tissue compatibility, as both D1 and D2 formulations showed similar responses. The presence of minor calcification areas and localized inflammation in some specimens was attributed to material surface irregularities rather than inherent incompatibility. These findings align with the study's aim of evaluating the safety of these cements in non-bony anatomical regions. The authors propose that these materials could be considered for further clinical applications where soft-tissue integration is required. The results provide a foundation for future investigations into the long-term performance of injectable cements in soft-tissue settings.